Updates

  1. 137 new fund letters and reports, each with its own page: Kayne Anderson Rudnick (48 market briefings, KayneCast episodes and TV commentaries), Shelton Capital Management (48 shareholder reports and a commentary), Lakehouse Capital (10 Small Companies Fund letters), Smead (5 newsletters), RIT Capital Partners (5 monthly commentaries), Kovitz, Legal & General, Generation, Hosking, Marram, Munro, Oldfield and others.
  2. 200 new fund letters and reports, each with its own page: Spheria (41 monthly reports), Peapack Private (41 weekly recaps and planning newsletters), Fort Washington (23), Polen Capital (15), Aristotle Pacific (14), Riverwater (13), Chou (10), Apollo Asia Fund (8, back to 1998), Personal Asset Trust, Rockwood Strategic, J Capital Research, I/O Fund, Penn Davis McFarland, Pomona and others.
  3. Investor pages have one Investments tab with shares, changes, % owned, class, market cap and Market cap and Status filters, a Funds tab listing each fund the firm runs, and assets under management from Form ADV. The Investors table shows AUM and current investments, and its search finds investors by what they hold.
  4. Filters, search and sort stay as you left them when you come back to a section. Person cards look like book cards. Company pages name their Investors tab Ownership. Kind and Sector filters use four kinds and GICS sectors with industries. Dead links left the Links tabs.
  5. 190 more investors from fiscal.ai's list, with their sites, letters, partners and 13F holdings; 556 more partner descriptions. Experts now lists only people.
  6. Fund letters lists 144 new documents from 23 firms, each with its own page: a summary, key insights and quotes. Among them: 37 BlackRock articles, 21 Value Partners monthly notes, eight Baron Capital letters, six Stone Sentinel letters to partners, seven Value Line portfolio manager Q&As, BNY's 2026 earnings releases and Starboard Value's 2026 conference presentations.
  7. 584 more investors, with their websites, 6,776 letters from their own sites, 1,385 partners with pages and the 13F holdings of 213 firms. New letters arrive daily from 290 more archives.
  8. Media and Companies filter by GICS sector and industry group, taken from the companies an episode or page names. 1,860 more company pages show a logo, the SEC's list included.
  9. The home page counts what the platform holds and lists features such as the document reader, the player and saved marks. Settings sits at the foot of the rail. Book cards are a quarter wider, so rows hold fewer. Companies drops the Named in filter, and the Role list in your account runs A to Z.
  10. Investor pages of 13 firms show their newsroom's latest posts. New 13F filings are read as the SEC publishes them.
  11. Investor pages have an Investments tab: 13,975 holdings for 105 investors, from their 13F filings with the SEC and their own portfolio pages, with status and sector. 7,338 more companies have a page of their own.
  12. A podcast or YouTube episode keeps playing while you move around the site, in a bar with skip, speed and volume. Media tables show each episode's length and description.
  13. Press releases come from each company's own newsroom (167 companies); SEC filings sit on the Filings tab. Tickers name their exchange, and a company's Experts tab includes guests whose episode description names it.
  14. Letter types now include Market commentary, Fact sheet, Interim report, Annual report, Proxy circular and Governance document. The reader opens over the whole window.
  15. Partners of investment firms have 2,836 appearances and 580 pieces of writing on their pages; Derek Sivers's page lists every book he rates, with his rating.
  16. Fund letters lists three Akre Focus shareholder reports: the ETF's annual report for the year to July 2026, its semi-annual report to January 2026 and the fund's semi-annual report to January 2025, each with its own page: a summary, key insights and quotes.
  17. 837 partners of 73 investment firms now have their own pages, with title, description, photograph and social accounts; Andreessen Horowitz partners' pages also list their writing on a16z.com.
  18. Company pages have a Press releases tab: 8,229 releases for 203 companies, from SEC filings and company newsrooms. Companies filter by For-profit or Non-profit. Own media is a table with filters. Media filters by sector and industry. Publication pages link their publisher in the description.
  19. The Unilever page's Letters tab shows what each fund letter says about Unilever, word for word with its page, and whether the letter is bullish, bearish, mixed or neutral. Filter by sentiment, and see 10 letters at a time.
  20. 492 more fund letters and 3,183 more articles show the day they were published, read from each letter's first page or each article's own page.
  21. The PDF reader has a search box: type words to see every match in the document and step through them. About 540 letters that were web pages, among them Oakmark's commentaries, Bill Miller's letters and Howard Marks's memos, now open in the reader.
  22. Person pages: recommendations open with tier 1 books; one button per organisation; transcripts sit on their episodes; the books on 129 reading lists joined the Recommends tabs.
  23. Companies lists every company with a ticker on the SEC's list, with a Source filter. A quote on a company page opens the letter at that page with the words marked. A company's Media tab lists only episodes that name it, and a new Own media tab lists its podcasts, publications and YouTube channel. Show pages link their publisher. A page opened from a table no longer shows that table's filters beside it.
  24. Company, investor and person pages show more of their social accounts: Facebook, TikTok, Bluesky, Medium, GitHub, Discord and podcast shows. Investor pages list every partner the firm's own team page names: 965 people across 73 investors, 98 for Andreessen Horowitz.
  25. About 170 more letters and papers open in the reader: Mohnish Pabrai's letters and transcripts from his site's new folder, and free copies of papers by Asness, Harvey, Altman, Lo and others from their own or their schools' sites.
  26. Every company a fund letter names has a page, with the letters and quotes that name it: 47 new pages, among them Atom Computing, Hugging Face, Rolls-Royce Holdings and Westinghouse Electric. Company pages have a Quotes tab.
  27. A person's Writing tab has a Type column and filter (Article, Essay, Transcript, Speech, Foreword, Interview and the rest), and Publication names only the publication that published each piece.
  28. Fund letters opens on the newest published letter, and a letter or paper found by search opens its own page here instead of the publisher's site.
  29. A letter or paper with a copy on the site opens its PDF over its page, with a button to open it in a new tab. Select text to highlight or underline it; signed-in readers keep their marks in their account. Each quote opens the PDF at its page with its words marked, and a Source link leads to the publisher's original.
  30. Fund letters lists 61 more documents, each with its own page: Fairfax's 2025 and 2026 interim reports, proxy circulars and 2025 annual report (with their French editions), 26 Charlie Munger meeting transcripts, talks and essays, Third Point's 2026 monthly reports and Malibu Life's interim results, and a Seth Klarman interview. Papers adds Richard Thaler's two 2020 editorials on nudges.
  31. Fund letters lists Lux Capital's letters for Q2 and Q3 2026, by Josh Wolfe, each with its own page: a summary, key insights and quotes.
  32. Fund letters lists Brookfield's letter to shareholders for Q3 2026, by Bruce Flatt, with its own page: a summary, key insights and quotes.
  33. Fund letters lists Howard Marks's memo of 11 November 2026, A Layman Thinks About AI, with its own page: a summary, key insights and quotes.
  34. Fund letters lists 118 more letters, each with its own page: 44 weekly commentaries by Jeremy Siegel from 2026, 31 issues of Van Tharp's newsletter from 2018, 23 Pabrai Investment Funds letters from 2021 to Q3 2026, 13 Efficient Frontier essays by William Bernstein, Oakmark's three 3Q 2026 commentaries, two Lindsell Train reports, a John Hussman comment and Third Point's Q3 2026 letter.
  35. 2,027 more books carry a one-line description in the Books table and on their pages; 7,067 of 7,715 have one, every tier 1, 2 and 3 book among them.
  36. Fund letters lists 187 more letters from 19 firms, among them Permanent Equity, Social Capital, Lux Capital, Square Peg, Bestinver, Cobas, Sequoia Fund, Marketfield and EquityCompass; each shows on its investor's page and has a page of its own.
  37. 2,928 more books carry a one-line description in the Books table and on their pages, so every tier 1, 2 and 3 book has one; 5,040 in all.
  38. Every publication on Newsletters has its own page: its writing, its writers, its staff and who recommends it. Investor pages have a Management tab; a company's Experts tab now leaves out its own people, who list under Management. Tabs on a phone move sideways only.
  39. Every fund letter and research paper has its own page: the thesis, the PDF, the companies and books it names, and for 176 letters and 24 papers so far a summary, key insights and quotes with their page.
  40. 99 books that no page listed now sit under their topics in Books, among them Caste, American Prometheus and Pale Blue Dot.
  41. Newsletters lists every newspaper, magazine, investment newsletter, journal and blog the reference holds, 442 in all, with the people who write there. The search box keeps your last 20 searches. You can create an account.
  42. 283 books that fund managers recommend in their letters are on the shelf, each with the letter's own words and page; investor pages have a Recommends tab.
  43. Person, company, investor and show pages link their own accounts on X, Threads, Instagram, LinkedIn, YouTube and Substack: 275 people, 552 companies and organisations, 88 investors and 478 shows.
  44. 716 more book recommendations name their source: the person's own reading list, letter, blog post, speech or interview, or an article that reports it. 232 of them quote the person's own words about the book, on the book card and on the book's page.
  45. Every US-listed company has a page with its SEC filings. Company pages list their experts and their management, past and present. Fund managers sit under Investors. Each show has a page of its episodes, and an episode page names its guests and hosts. Biographies lists groups, then people. Breadcrumbs show where a page sits.
  46. Media lists every podcast episode, video, interview and talk, over 10,000, by person, company, publisher and event; each filter searches its own choices. Books opens on its table, then Browse, then Authors and Recommenders. A filter's count no longer covers its arrow.
  47. A book that no company, country or subject page lists shows its topics under Where it sits in the reference. On a phone, a page's tabs scroll sideways only. Descriptions read the same on every page. See them in the Experts tab lists every expert the page names.
  48. Every podcast episode, video and interview has its own page with a video or audio player and a link to the source. Investor pages show each company's sector and market cap; firms such as Berkshire Hathaway have one page that holds their letters and their company tabs. Letters tabs filter by company and search the theses. Companies filter by Public, Private and Defunct and link each company's website.
  49. Every tab, view and search has its own address, such as /books/table/asset or /letters/companies, so Back works and a link opens the same place. Page addresses no longer end in .html. Fund letters, Investors, Companies and Papers load about a fifth of the data they did.
  50. Fund letters has a Companies tab: every company the letters name, with its market cap, sector, country, and how many letters and investors name it. Investor pages link each investor's website. Lists in table cells end with “… and N more” at every width.
  51. 1,120 more book summaries; descriptions for 373 papers; pages for 137 more companies, each with the fund letters that discuss it; 215 official photographs; search has its own page.
  52. 411 more books have a summary; person pages list 930 more of the books they wrote; 147 people show their official photograph.
  53. Every investor has a page with its letters and the companies they discuss; company pages list the investors whose letters name them.
  54. A Companies section at the top of the rail lists every company the books, experts and fund letters name.
  55. Person pages list letters, writing, profiles and links as sortable tables with filters, and show each person's companies as links; Fund letters show each letter's description in its own column.
  56. Experts show a checked job title and a short description of each person; 30 more people have photographs.
  57. Every company, fund, university and publication the experts work for has a page listing the people there.
  58. Fund letters show each letter's thesis and filter by it; 225 person pages list the essays, columns and newsletter issues the person wrote.
  59. Person pages list every essay and newsletter issue a person wrote, and their own books as a table in List view.
  60. Recommends shows the five largest kinds of book and the rest under More; browse pictures load sooner.
  61. Podcasts and talks link the original episode, filter by Audio and video or Press, and list each publisher once.
  62. Pages are wider, Recommends has List and Grid, and a filter clicked again turns off.
  63. Book cards sit in a ruled grid with Open Library and Goodreads links and each book's one-line note.
  64. Funds is now Investors; each investor's styles are buttons that filter the table.
  65. Podcasts and talks on a person's page filter by year and publisher and show as a list or a grid of pictures.
  66. Quotes show only people's own words: 472 summaries written by list sites are gone.
  67. Country pages open from Browse again, and every link on the shelf lands on a page.
  68. Subject and person pages show their sections as tabs, and each book appears once on a person's page.
  69. Book cards show the quote, who said it and the source; grids show five cards to a row.
  70. On a phone, a menu holds the sections, search, Updates, Feedback and dark mode.
  71. Feedback takes a screenshot of the page with no browser prompt, opens a screenshot full size when you click it, and clears itself once sent.
  72. Book cards are centred, search names the topic each book sits in, and any text cut short shows whole on hover.
  73. Search groups its results by kind: people, companies, geographies, subjects, topics, books, funds, fund letters and papers.
  74. The Books table lists who recommended each book by name, and the browser tab names the section you are in.
  75. Feedback can take a screenshot of the page, or one you paste or choose, and opens in the corner beside Updates.
  76. Each rail button reopens its section where you left it, and Browse, Table and People show on every book and subject page.
  77. Filters grey out choices that hold nothing instead of hiding them, and Books › People filters by authors or recommenders.
  78. Feedback takes a subject line and up to three screenshots.
  79. Biographies are grouped by the person they are about: 41 new pages, from Abraham Lincoln to Lee Kuan Yew.
  80. Sport splits into 23 sports, and Religion into one topic per faith.
  81. Book lists show as cards: the cover, one recommendation quote and every recommender by name.
  82. Seventeen subjects that had two or three pages under different names now have one page each.
  83. Every page lists its Experts as authors and recommenders, with a link to them on the Experts tab.
  84. Economics, Financial history, Financial panics and Accounting are subjects of their own, with one page per financial crisis.
  85. Book, person and subject pages open inside the app, so the tabs stay in view.
  86. 996 more book covers, and photographs or logos for 227 more people and companies.
  87. Books › Browse shows every subject as cards, and the rail holds Fund letters, Papers, Experts, Books and Funds.
  88. Every topic over 150 books splits into narrower topics, each with a page of its own.

Send feedback

What is it?
Screenshots, up to 3 (optional)
or paste one with Ctrl+V

We use your email only to reply to you.

R

Podcast · 58 episodes in the reference, 2020 to 2026

Raising Health

Published by Andreessen Horowitz, a16z Bio + Health

Episodes

The AI-Native Health Plan | UnitedHealth Group’s Dan KueterJulie Yoo5 November 2026Can AI finally make healthcare cheaper? UnitedHealth Group Chief Commercial Officer Dan Kueter believes it can, potentially within a single-digit number of years, but only once AI moves beyond automating existing administrative work and starts enabling things the healthcare system couldn’t do before. At a16z BUILD, Dan joins General Partner Julie Yoo to discuss a generational shift in employer-sponsored health insurance, why self-funded plans are becoming accessible to smaller employers, and how AI is changing everything from underwriting and distribution to consumer navigation. They also get into UnitedHealthcare’s goal of eliminating 30% of prior authorizations, what a “touchless” version could eventually look like, and why personal AI agents could become a new front door to healthcare, forcing insurers to meet consumers wherever they choose to interact. Resources: Follow Dan Kueter on Linkedin: https://www.linkedin.com/in/dankueter/ Follow Julie Yoo on X: https://x.com/julesyoo Learn more about a16z Bio + Health: https://a16z.com/bio-health/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
The Next Era of Health Data: AI, Open APIs, and the End of the EHR OligopolyJulie Yoo29 October 2026Healthcare spent the last 15 years digitizing medical records. Now the challenge is making that data useful to patients, AI agents, and new health technology companies. National Coordinator for Health IT Dr. Tom Keane says the next phase is about interoperability, patient access, and lowering barriers for new entrants. Tom joins a16z’s Julie Yoo and Colin Rom to discuss how healthcare data can move more easily through APIs and TEFCA, how wearables and AI-generated data fit in, and where privacy and security concerns can become competitive moats. And when Julie asks when AI might produce a serious new competitor to today’s dominant electronic health record companies, Tom predicts: within one to two years. Resources: Follow Thomas Keane on LinkedIn: https://www.linkedin.com/in/thomas-keane-b41a5012/ Follow Julie Yoo on X: https://x.com/julesyoo Follow Colin Rom on X: https://x.com/CF_Rom Office of the National Coordinator for Health IT: https://healthit.gov Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Building the Store for Healthcare | General MedicineVineeta Agarwala22 October 2026AI is making healthcare advice abundant. But what happens when you actually need to act on it? General Medicine CEO TJ Parker argues that the new bottleneck is getting the lab, booking the specialist, filling the prescription, or understanding what any of it will cost. At BUILD 2026, a16z General Partner Vineeta Agarwala sits down with TJ to unpack General Medicine's vision for a healthcare “store”: one place where patients can understand their options, prices, and insurance coverage, then actually get care. They discuss why convenience can materially change patient behavior, how AI can connect medical records and benefits to the right next step, and what TJ learned building PillPack and Amazon Pharmacy about making a complicated healthcare system feel simple. Resources: Follow TJ Parker: https://x.com/tjparker Follow Vineeta Agarwala: https://x.com/vintweeta Learn more about General Medicine: https://generalmedicine.co/ Learn more about a16z Bio + Health: https://a16z.com/bio-health/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Moderna CEO Stéphane Bancel on the Next Era of mRNAJorge Conde2 September 2026a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck’s individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines. Stéphane explains how the treatment works by sequencing an individual patient’s tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack. They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna’s longer-term work applying mRNA to rare genetic and autoimmune diseases. Resources: Follow Stéphane Bancel on LinkedIn: https://www.linkedin.com/in/st%C3%A9phane-bancel-8185251/ Follow Jorge Conde on X: https://x.com/JorgeCondeBio Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Healthcare Will Benefit Most from AI | Julie Yoo on StartUp HealthJulie Yoo21 April 2026This episode originally aired on StartUp Health. Unity Stoakes speaks with Julie Yoo, general partner at a16z, about why healthcare is poised to benefit more from AI than any other industry, how the business profile of health tech companies has fundamentally shifted, and what founders need to show up with today to stand out at the seed and Series A stages. Resources: Follow Julie Yoo on X: https://x.com/julesyoo Follow Unity on X: https://x.com/unitystoakes Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Andrew Huberman: Peptides, Sleep Tech, and the End of ObesityDaisy Wolf9 March 2026Daisy Wolf speaks with Dr. Andrew Huberman, professor of neurobiology and ophthalmology at Stanford University and host of the Huberman Lab podcast. They discuss how the pandemic sparked a consumer health revolution, the emerging peptide and GLP landscape, what the science actually says about focus drugs, and the neurotechnologies Huberman believes will let us write to our own biology within the next five years. Resources: Follow Andrew Huberman on X: https://twitter.com/hubermanlab Follow Daisy Wolf on X: https://twitter.com/daisydwolf Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Show on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Show on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures . Hosted by Simplecast, an AdsWizz company.
Rebuilding Behavioral Health’s Operating System with AIDaisy Wolf, Eva Steinman2 March 2026a16z Partners Daisy Wolf and Eva Steinman talk with Zach Cohen and Raymond Wang, cofounders of Ease Health, a company building an AI operating system for behavioral health that combines CRM, EHR, and revenue cycle management into a single platform. They discuss why behavioral health software has lagged behind, what it means to build AI native versus AI integrated, and why Zach left his job as an investor at a16z to go build in this space. They also cover how Ease plans to replace the dozen software vendors most practices rely on today. Resources: Follow Daisy Wolf on X: https://x.com/daisydwolf Follow Eva Steinman on LinkedIn: https://www.linkedin.com/in/eva-steinman/ Follow Zach Cohen on X: https://x.com/zachcohen25 Follow Raymond Wang on LinkedIn: https://www.linkedin.com/in/arrays/ Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends!
AI in Healthcare: The Leapfrog OpportunityJulie Yoo24 February 2026At the Oliver Wyman Health Innovation Summit 2025, Julie Yoo, General Partner at a16z Bio + Health, makes the case that healthcare is uniquely positioned to benefit from AI more than any other industry. She argues that healthcare's historical underinvestment in technology is now an asset, enabling the industry to leapfrog directly to AI-native models of care delivery with unprecedented speed and scale. Resources: Follow Julie Yoo on X: https://x.com/julesyoo Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Show on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Show on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures . Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Ambience CEO Nikhil Buduma on AI in Clinical WorkflowsJulie Yoo20 February 2026a16z general partner Julie Yoo talks with Nikhil Buduma, CEO and cofounder of Ambience Healthcare, to discuss how AI is transforming clinical workflows. They cover the early days of deep learning, why Ambience started by running a medical practice before building a platform company, and what it takes to achieve high clinician adoption rates at major academic medical centers. They also dig into the challenge of building products when AI capabilities change every few months, the real ROI that's finally converting CFOs, and why this might be the moment to reimagine the legacy EHR stack. Resources: Follow Nikhil Buduma on X: https://twitter.com/nkbuduma Follow Julie Yoo on X: https://twitter.com/julesyoo Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Show on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Show on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed.
Building the Marketplace for AI’s Most Valuable AssetDaisy Wolf, Eva Steinman17 February 2026a16z investors Daisy Wolf and Eva Steinman talk with Bobby Samuels, cofounder and CEO of Protege. They discuss the myth that we've run out of data for AI, how Protege connects healthcare systems and other data holders with the major AI labs, and why real-world data beats synthetic data for training models. Bobby also covers the growing demand for eval datasets, expanding beyond healthcare into video and audio, and what he's seeing from the biggest AI companies as they race to acquire training data. Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures . Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Making Healthcare Affordable for 80 Million AmericansJulie Yoo5 February 2026Recently, a16z Bio + Health general partner Julie Yoo spoke with Nikita Singareddy, cofounder of Fortuna, and Florian Otto, cofounder of Cedar. They talked about why healthcare affordability is reaching a breaking point, how AI voice agents are transforming patient financial experiences, and what it will take to leapfrog decades of administrative burden in Medicaid—from 30-page paper applications to legacy technology systems built in the 1990s to the real opportunity for giving every American a "five-star healthcare experience." Resources: Follow Julie Yoo on X: https://twitter.com/julesyoo Follow Nikita Singareddy on X: https://twitter.com/singareddynm Check out Fortuna: https://www.fortunahealth.com/ Follow Florian Otto on X: https://twitter.com/flottobrasil Check out Cedar: https://www.cedar.com/ Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends!
Healthcare 2026: AI Doctors, GLP-1s, and Insurance DefectionJay Rughani27 January 2026Out-of-Pocket is a healthcare education company founded by Nikhil Krishnan that helps people understand how healthcare works and how to navigate it in practice. In this episode, a16z investing partner Jay Rughani and Nikhil discuss why health insurance is losing its role as the default way people access care. They explain how rising costs are pushing more consumers to pay out of pocket for diagnostics, preventive care, and navigation. The conversation also looks at what this shift means for startups, AI-powered tools, regulation, and access as healthcare continues to move beyond insurance. Resources: Follow Jay Rughani on X: https://twitter.com/JayRughani Follow Nikhil Krishnan on X: https://twitter.com/nikillinit Read Out of Pocket’s 2026 Predictions: https://www.outofpocket.health/p/out-of-pockets-2026-predictions Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://x.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Podcast on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund.
How AI Cut Healthcare Burnout by 70%Julie Yoo4 December 2025In this episode, a16z GP Julie Yoo sits down with Peter McCanna, CEO of Baylor Scott & White Health, to break down how one of America's largest health systems is transforming from a supply-driven "walled castle" to a customer-centric ecosystem, and how it's achieving a 10% operating margin while most hospitals struggle to stay in the black. They get into why helping his father navigate healthcare convinced Pete the entire system is fundamentally broken, what differentiates academic medical centers from community health systems, and why traditional hospital economics root out essential services like behavioral health. Peter also explains how ambient AI reduced physician burnout rates by 70%, why AI will eventually replace any job involving human-screen interaction, and what he looks for in startup partnerships beyond just TAM and business fundamentals. Resources: Follow Peter on LinkedIn: https://www.linkedin.com/in/peter-mccanna-784619104 Follow Julie on X: @julesyoo Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends!
How to Build This Generation's Big Pharma CompanyJorge Conde17 November 2025Drug discovery has doubled the flow of candidates, but approvals remain roughly flat. The constraint is development, not discovery. In this episode, a16z General Partner, Jorge Conde talks with Formation Bio cofounder and CEO Ben Liu about building a modern pharma company around clinical execution. They discuss Formation Bio’s hub-and-spoke model for acquiring and advancing assets, how AI compresses trial timelines and costs, picking winners, regulatory strategy, and what it would take to move from about 50 approvals a year to many more. They also touch on global competition and why clinical proof still drives value in today’s market.\ Timecodes: 0:00 Introduction 0:38 Why Formation Bio? Origins and Mission 1:12 The Real Bottleneck: Clinical Development 4:56 Formation Bio’s Business Model 7:50 Picking Winners: The Art and Science of Drug Selection 11:54 First-in-Class vs. Best-in-Class Strategies 14:04 Overcoming Regulatory and Market Challenges 17:26 The Stakes: Can We Approve More Drugs? 19:07 How Formation Bio Cuts Cost and Time 21:43 AI’s Role in Drug Development 25:10 The Future: From 50 to 500 Drug Approvals? 35:18 Global Competition: The Rise of China 39:28 The Path Forward: Data, Regulation, and Access 41:47 Conclusion: Realizing the AI Revolution in Pharma Resources: Find Ben on X: https://x.com/BenjamineYLiu Find Jorge on X: https://x.com/JorgeCondeBio Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends!
CVS Health: Building Healthcare’s Consumer PlatformJulie Yoo10 November 2025Josh Weiner left Meta to return to CVS Health with two painful realizations: consumers don't manage their health—they expect it, and the healthcare market fundamentally violates every principle of economics. In this conversation with a16z's Julie Yoo, the CVS Senior VP explains why 50% of Americans can't afford a healthcare emergency, how CVS is becoming a platform to solve structural healthcare problems, and why the future depends on consumers finally controlling their own health data. Timecodes: 0:00 The Healthcare Market Isn't Functioning 2:30 Consumers Don't Manage Health, They Just Expect It 3:39 Why Consumer Playbooks Die in Healthcare 5:41 Motion vs Progress: The Innovation Illusion 8:46 Platform Philosophy: "It Takes a Village" 11:38 The Vaccine Paradox Under One Roof 19:37 The 40% Hidden Reality: Healthcare Is Caregiving 21:04 The Deductible Comprehension Crisis 22:10 "This Does Have an Expiration Date" 24:40 The Health Passport Future Resources: Find Josh on LinkedIn: https://www.linkedin.com/in/joshweiner2/ Follow Julie on X: https://x.com/julesyoo Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends!
Dyno Therapeutics: Empowering Patients with Genetic AgencyJorge Conde7 November 2025For the first time in human history, we can diagnose thousands of genetic diseases—often for under $1,000—but we still can't treat most of them. The problem isn't understanding what's broken; it's delivering the fix to the right cells. Eric Kelsic, CEO of Dyno Therapeutics, joins a16z's Jorge Conde to explain how AI-designed protein shells are solving gene therapy's delivery crisis. They explore why Huntington's patients can now get 15 extra years of healthy life, how Dyno inverted the liver-to-brain delivery ratio by 1000x, and why capsids evolved by nature are now being designed by machine learning models trained on millions of variants. Eric introduces the concept of genetic agency—humanity's first-ever ability to take action at the DNA level—and details why solving delivery for common diseases will make ultra-rare disease treatments economically viable. Plus: what happens when gene therapy requires neurosurgery today but could be a simple injection tomorrow, why recent deaths in clinical trials prove we need better technology now, and how genetic medicine could become as routine as surgery within our lifetimes. Resources: Follow Eric on X: https://x.com/ekelsic Follow Jorge on X: https://x.com/JorgeCondeBio Learn more about GATC 2025: https://www.dynotx.com/gatc2025 Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends!
Value-Based Oncology at Scale: Inside Thyme CareJay Rughani, Vineeta Agarwala29 September 2025Cancer care in the U.S. costs over $250 billion each year, and nearly 2 million Americans receive a new diagnosis annually, yet too often the journey begins with silence: no call, no plan, no guide. In this episode, a16z’s Vineeta Agarwala and Jay Rughani talk with Thyme Care leaders Robin Shah (cofounder and CEO), Bobby Green, MD (president and CMO), and Brad Diephuis, MD (president and COO) about rebuilding oncology around the patient. They cover where the system breaks, how navigation plus value-based contracts align incentives, how AI can extend clinicians, and what scale looks like today, more than 83,000 active patients. A concise blueprint for truly patient-centered cancer care. Timecodes: 0:00 Introduction 1:47 Personal Stories & Early Days of Time Care 5:27 Building the Team & Mission 7:07 The Patient Journey: Where the System Fails 9:58 Why Tech Hasn’t Solved Cancer Care (Yet) 15:45 Scaling Impact: Growth & Partnerships 17:45 How Time Care Works: Value-Based Care Explained 23:15 Technology, AI, and the Human Touch 37:06 Building for the Future: Generational Impact Resources: Find Robin on LinkedIn: https://www.linkedin.com/in/robin-shah-8072bb35 Find Bobby on LinkedIn: https://www.linkedin.com/in/drbobbygreen/ FInd Brad on LinkedIn: https://www.linkedin.com/in/bdiephuis/ Find Vineeta on X: https://x.com/vintweeta Find Jay on X: https://x.com/JayRughani Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends!
Engaging the Unengaged at Home with Max Cohen and Cameron BeharJulie Yoo22 July 2025In this episode, Sprinter Health co-founders Max Cohen and Cameron Behar sit down with Julie Yoo to unpack how their home-based care model reaches underserved populations and reintegrates “the unengaged” into the healthcare system. From starting with blood draws in living rooms to scaling a high-complexity, tech-enabled logistics platform, they share how operations, empathy, and human connection power their success. The duo reflects on the constraints and regulatory nuance of healthcare, revealing how humility, intentional culture-building, and pragmatism give tech-native founders an edge. Listeners will walk away with tactical advice on balancing scrappiness with long-term scalability, architecting tech-clinical collaboration, and applying AI to augment—not replace—human-delivered care. For healthcare entrepreneurs navigating systems transformation without deep domain roots, this candid conversation is both roadmap and reality check. Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Streamlining the Patient Referrals Chain with Trey HoltermanDavid Haber, Jay Rughani20 June 2025In this episode, Tennr cofounder and CEO Trey Holterman sits down with a16z’s David Haber and Jay Rughani to unpack one of healthcare’s most overlooked pain points: patient referral logistics. When a patient is referred to a specialist and told that the specialist will follow up with them, what happens next? A convoluted system sometimes involving dozens of staff and multiple portals, all of which may or may not result in the specialist actually following up. Trey shares how Tennr leverages AI to automate the complex, unstructured workflows that delay patient care and burden frontline staff. Tennr's goal is to meaningfully increase patient conversions—ensuring more people get the treatment they need, faster. Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
From Chaos to Clarity in Data with Malinka WalaliyaddeJulie Yoo10 June 2025What if one of healthcare’s most complex administrative challenges—revenue cycle management—was reframed as a data science problem? In this episode, Malinka Walaliyadde, cofounder and CEO of AKASA, joins Julie Yoo to unpack how large language models have the potential to transform hospital revenue by automating highly nuanced coding and billing workflows. Malinka discusses how AI is finally making it possible to extract simplicity from a sea of clinical complexity and unstructured data, simplifying the flow of dollars through the healthcare system and freeing staff to focus on patients. Plus: Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Fueling Innovation with Data with Arif NathooJay Rughani, Jorge Conde13 May 2025Arif Nathoo, cofounder and CEO of Komodo Health, joins Jorge Conde and Jay Rughani to explore the transformative potential of healthcare data in reshaping biotech and healthcare innovation. Arif reflects on a decade-long journey of unlocking the power of fragmented healthcare data, delving into Komodo Health’s “full-stack thesis” — a strategy that combines rich datasets, advanced analytics, and AI to enable life sciences companies, payors, and providers to make better decisions at scale. Together, the three also discuss leveraging predictive AI to identify undiagnosed patients and optimize care delivery. Arif also shares actionable advice for founders, from picking the right partner to staying steadfast in the vision. Plus: Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
The Paradox of U.S. Healthcare with Marc AndreessenMarc Andreessen29 April 202534 minJoin a16z general partners Marc Andreessen, Julie Yoo, and Vijay Pande for an incisive exploration of what's driving—and stalling—transformation in healthcare. With the industry now consuming nearly 20% of U.S. GDP yet delivering poor outcomes relative to other developed countries, is technology the remedy or a red herring? This episode, cross-posted with the a16z podcast, dissects the inertia holding healthcare back, from regulatory bottlenecks to misaligned incentives, while offering actionable insights for entrepreneurs navigating this complex space. Plus: Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
The (Epic) Arc of a Patient Journey with Seth HainJulie Yoo15 April 2025Seth Hain, SVP of R&D at Epic, joins a16z Bio + Health general partner Julie Yoo to explore technology in healthcare. Reflecting on over two decades of industry shifts, Seth shares how Epic has transitioned from enabling integrated systems within health systems to driving cross-ecosystem collaboration and rapid innovations like generative AI. They also discuss orchestration of patient care across diverse settings, the transformative impact of AI on clinical workflows, and whether "electronic health record" is really the best term for clinical record-keeping software. Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Building for the Healthcare Consumer with Elliot CohenJulie Yoo1 April 2025Elliot Cohen, cofounder of PillPack, joins Julie Yoo, a16z Bio + Health general partner. Together, they discuss Elliot's experience designing and building a consumer-first pharmacy alongside TJ Parker. Elliot's journey with PillPack began when he noticed his father struggling with a mail-order pharmacy that couldn’t get the simplest thing right: the correct version of a pill. Elliot shares the nitty-gritty of building a consumer-centric business in healthcare, including how they had to adapt CSV files and cake boxes to get their initial product off the ground, and how they balanced the needs of a healthcare system with the desires of their customers. Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
An Ironman Suit for Doctors with Muthu AlagappanJulie Yoo25 February 2025Dr. Muthu Alagappan, MD, founder and CEO of Counsel Health, joins Julie Yoo, a16z Bio + Health general partner, to dive deep into the company's vision for revolutionizing healthcare through AI-powered asynchronous care. Together, they unpack how Counsel enables on-demand access to real doctors for instant medical guidance, lessening patient reliance on Google and alleviating system inefficiencies and physician burn-out. Dr. Alagappan also explores the duo of efficiency and scale that large language models bring to clinical workflows, making its “clinician cockpit” a superhuman support system for physicians. More in "The Opportunity for Healthcare in a Post-LLM World": Voice AI: Solving Healthcare's Workforce Challenges with Ankit Jain Super Staffing in Healthcare with Munjal Shah Transforming Clinical Trials with Alexander Saint-Amand Plus: Learn more about a16z Bio+Health Learn more about & Subscribe to Raising Health Find a16z Bio+Health on LinkedIn Find a16z Bio+Health on X Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Scaling Medicaid Innovation with Afia Asamoah, Rajaie Batniji, and Sanjay BasuVineeta Agarwala14 January 2025Rajaie Batniji, MD, PhD, Afia Asamoah, JD, and Sanjay Basu, MD, PhD, cofounders of Waymark, join Vineeta Agarwala, MD, PhD, a16z Bio + Health general partner, to discuss their transformative approach to Medicaid care delivery. This episode dives into their rising risk signal prediction framework, where cutting-edge machine learning predicts patient needs and enables community-based care teams to reduce preventable ER visits and improve health outcomes at scale. The team recently published their real-world results—including a 23% reduction in unnecessary acute care—in the New England Journal of Medicine Catalyst. Additional resources: Supporting Rising-Risk Medicaid Patients Through Early Intervention , NEJM Catalyst The Body Economic : Why Austerity Kills, by David Stuckler and Sanjay Basu Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Mastering Data with Sajith WickramasekaraJay Rughani, Jorge Conde12 November 2024In this episode, a16z partners Jorge Conde and Jay Rughani sit down with Sajith Wickramasekara, CEO and cofounder of Benchling, to unpack the evolution of Benchling from idea to transformative software platform. Saji discusses his journey from software engineer to building Benchling and digitizing biotech workflows for industry giants like Sanofi. Together, they also talk about the increasing complexity of biology, the expanding role of AI in drug discovery, and the power of well-structured data. The 21st century isn't just the century of advanced biology—it's also the era of creating tools that supercharge scientific discovery. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
The Freedom to Choose Your Own Insurance with Chris Ellis and Adam StevensonJay Rughani22 October 2024Chris Ellis, CEO and Adam Stevenson, president, both cofounders of Thatch, join Julie Yoo and Jay Rughani of a16z Bio + Health. In early 2020, a new policy called ICHRA altered the insurance market, which had remained largely unchanged for decades. As you’ll hear in the episode, it’s been slow to catch on — but the cofounders of Thatch think it’s a game changer. Together, they discuss these key takeaways: Consumers as a growing class of payor: Traditionally employers shouldered healthcare costs, but now consumers are paying more out of pocket and making purchasing decisions directly for their health coverage. ICHRA represents a major shift, allowing companies to give employees tax-free dollars to shop for personalized health plans. Distributed teams and geographic diversity are creating friction in providing effective healthcare via traditional group plans. Employees may find that certain doctors aren’t covered and plans aren’t tailored to their needs, making ICHRA an increasingly attractive option for employers. The fintech intersection How do you make spending healthcare dollars easy, secure, and efficient? By leveraging fintech solutions that ensure employees use healthcare dollars on what matters most for them. This alignment between fintech and healthcare could enable more flexible, localized plans , with individuals choosing the add-ons that work best for them at that moment in their lives. Hosted by Simplecast, an AdsWizz company.
Why Tech Must Disrupt Healthcare NowDaisy Wolf8 October 2024In this episode, Vijay Pande and Daisy Wolf of a16z Bio + Health join a16z Podcast host Steph Smith to make a provocative case for why technologists—not just medical professionals—are key to reinventing healthcare. They argue that to transform a sector representing 20% of U.S. GDP, innovation must move beyond curing diseases toward tackling healthcare’s broken systems. By likening the healthcare industry to a logistics challenge, Vijay and Daisy outline how technologists can leverage their expertise in consumer engagement, operational efficiency, and AI to drive the next frontier of health innovation. They also explore high-impact opportunities like improving patient experiences and deploying AI for behavioral change at scale. If you’re ready to explore new paths in healthcare, this episode is essential listening for understanding the powerful role technologists can play in shaping its future. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Harnessing Water Dynamics for Drug Design with Michael Crackower and Jason BurchVineeta Agarwala20 August 2024Michael Crackower, PhD, Chief Scientific Officer of Ventus Therapeutics, and Jason Burch, PhD, join Vineeta Agarwala, MD, PhD, general partner at a16z Bio + Health. Together, they talk about how Ventus approaches drug discovery and why they believe we’re in the early stages of small molecule innovation. Specifically, we’ll hear about the ReSOLVE platform, which enables the drug hunting team to more accurately design and iterate on small molecular compounds for therapeutic applications. They also talk about the current candidates in the pipeline and how they’re able to go from idea to IND in record time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
The History and Future of CAR T with Bruce LevineJorge Conde6 August 2024Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, joins Jorge Conde, general partner, and Ginger Liau, partner at a16z Bio + Health. Bruce talks about how his time working in a lab at the Children’s Hospital of Philadelphia inspired him to work on translational therapies. Together, they also discuss barriers to access for cancer therapeutics and how the fight against cancer is progressing. Additional disclosures for Bruce include: Scientific Advisory Boards: Avectas, Capstan (Chair), Immuneel, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, ThermoFisher Pharma Services, UTC Therapeutics. Scientific Advisor: Kite. Past: Akron, Vycellix Co-Founder and equity holder: Tmunity Therapeutics (acquired by Kite), Capstan Therapeutics Board of Directors: Alliance for Cancer Gene Therapy Conflict of interest is managed in accordance with University of Pennsylvania policy and oversight. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Protecting the Golden Age of Medicine with John CrowleyJohn Crowley, Jorge Conde23 July 202431 minJohn Crowley, President and CEO of Biotechnology Innovation Organization (BIO), joined Jorge Conde, general partner at a16z Bio + Health. Together, they talk about John’s entry into biotech and his time as a founder, all motivated by his determination to discover and develop a treatment for his children, who have Pompe disease. They also talk about John’s priorities as head of BIO and how that could translate into policy. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
A Fatal Inheritance with Lawrence IngrassiaVineeta Agarwala16 July 2024Lawrence Ingrassia, author and journalist, joins Vineeta Agarwala, general partner, and Kris Tatiossian, editorial lead at a16z Bio + Health. Together, they discuss Larry's recently published book, A Fatal Inheritance: How A Family Misfortune Revealed A Deadly Medical Mystery . In the book, Larry recounts the story of the p53 cancer suppressor gene, also known as the “guardian of the genome.” Mutations in this gene, which can be inherited, remove a natural tumor defense, making it more likely for an individual to get cancer during their lifetime. He tells the story of the search for this gene and the scientists who unlocked the mystery of high familial incidences of cancer, Drs. Li and Fraumeni. He also shares a more personal aspect of the story: many members of his family inherited Li-Fraumeni Syndrome and suffered from multiple cancers themselves.
The Science and Supply of GLP-1s with Chronis ManolisDaisy Wolf11 June 2024Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan, joins Julie Yoo, general partner, Daisy Wolf, investment partner, and Will Shrank, venture partner, of a16z Bio + Health. Together, they discuss how payors and providers are thinking about anti-obesity medications, as well as pricing and prior authorization considerations. This is the third episode in our series on the science and supply of GLP-1s. Listen to last week’s episode to hear from Brooke Boyarsky Pratt, founder and CEO of knownwell, about the importance of patient-centric medical homes. The week before, we spoke with Carolyn Jasik, Chief Medical Officer at Omada Health, on GLP-1s from a clinical perspective. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
The Science and Supply of GLP-1s with Brooke Boyarsky PrattVineeta Agarwala4 June 2024Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health. Together, they talk about the value of obesity medicine practitioners, patient-centric medical homes, and how Brooke believes the metabolic health space will evolve over time. This is the second episode in our series on the science and supply of GLP-1s. Listen to last week's episode to hear from Carolyn Jasik, Chief Medical Officer at Omada Health, on GLP-1s from a clinical perspective.
Unleashing CAR T with Carl JuneJorge Conde7 May 2024In this episode, Carl June, MD, pioneering immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health. Together, they discuss Carl's work on CAR T, a remarkable story of the first use of CAR T in a pediatric patient, and Carl's take on where oncology treatments are headed next. Though this episode was originally published in September 2023, back when we were called Bio Eats World, we’re republishing it during this year’s ASGCT conference, where the latest advances in cell and gene therapy—like what Carl describes—are shared and discussed. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Longevity as a Health Asset with Tom HaleDaisy Wolf30 April 2024Tom Hale, CEO of ŌURA, joins Vijay Pande, founding partner, and Daisy Wolf, investment partner at a16z Bio + Health. Together, they talk about the potential of wearables to change behavior, and how that can affect health. They also discuss how AI could maximize the usefulness of wearables and power the insights provided to wearers. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Grand Challenges in Healthcare AI with Vijay Pande and Julie YooJulie Yoo9 April 2024Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today. The discussion covers the implications of AI integration in healthcare workflows, AI as a potential catalyst for value-based care, and the potential for innovation in clinical trials. They also talk about the AI startup they each wish would walk through the door.
Dark Genome Hunting with Rosana Kapeller and Marty TaylorVineeta Agarwala12 March 2024Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health. Together, they discuss Rosana and Marty's recent publication regarding a virus-like element in our genome known as LINE-1. LINE-1, part of our "dark genome," was ignored as junk DNA for years, but is increasingly recognized to contribute to the pathology of autoimmunity, cancer, neurodegeneration, and aging. Rosana and Marty discuss how the discovery was made as well as how Rome Therapeutics is developing a platform to target LINE-1 and other factors that are part of the "dark genome" for the treatment of disease. Additional reading: Structures, functions and adaptations of the human LINE-1 protein Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Metrics for a Complex Machine with Josh ClementeDaisy Wolf13 February 2024Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health. In this episode, engineer-turned-entrepreneur Josh charts his journey from SpaceX and Hyperloop to cofounding metabolic health-focused company Levels. With a relentless drive for data-led health monitoring, Josh highlights the potential of wearable tech for tracking various biomarkers. Josh, Vijay, and Daisy also discuss how AI can simplify complex wearables data into a comprehensible and actionable health profile, with the potential to democratize healthcare technology. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Transitioning From Gymnast to Investor with Aly RaismanDaisy Wolf6 February 2024Former gymnast and current investor Aly Raisman joins general partner Julie Yoo and investment partner Daisy Wolf of a16z Bio + Health. In this episode, Aly Raisman shares her quest for healthier living—physically, mentally and financially—on her journey from gymnast to a business investor. Having herself transitioned from an intensely structured routine, Aly emphasizes the need for more open conversations about mental health and financial literacy. She speaks passionately about the gap in women’s health solutions and hopes to inspire entrepreneurs to create impactful businesses. Aly’s experiences as a patient, survivor, and global figure adds a unique dimension to her perspective as an investor. This candid conversation with both Aly and Julie Yoo sheds light on Aly’s passion for more education within the investment space offering invaluable insights for entrepreneurs, particularly in biotech and healthcare. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Drag & Drop Genome EditingJorge Conde16 January 2024Today's episode features the CEO of Tome Biosciences, Rahul Kakkar, alongside John Finn, CSO of Tome. They are joined by Jorge Conde, general partner at a16z Bio + Health. Together, the three of them discuss the technology underlying Tome's work, known as PASTE, a genome editing technique. They also dive deep into how this technology could be applied to help patients, making cell therapy more accessible for more people. Editorial note: We mistakenly identified Rahul Kakkar and John Finn as the co-founders of Tome Biosciences. In reality, Rahul serves as the CEO, and John is the CSO of Tome. The actual co-founders of Tome Biosciences are Jonathan Gootenberg and Omar Abudayyeh. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Gate Unveiling with Jordi Mata-FinkBen Portney, Vineeta Agarwala5 December 2023Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health. In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed 'molecular gates.' His company, Gate, is working to exploit a previously uncharted avenue in cell biology—the secretory translocon—for therapeutic intervention. This approach has the potential to combat diseases otherwise resistant to existing therapeutics. Jordi also imparts valuable insights on the power of platform-based problem-solving and team building. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Unleashing CAR T with Carl JuneJorge Conde12 September 2023Carl June, MD, an immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health. Together, Carl and Jorge talked about Carl's pioneering work in CAR T therapy — including the terrifying moment where he thought he had accelerated one of his patient's deaths, how he started working in human immunology, and his take on where cancer treatment is headed next. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Becoming a Partnership Pioneer with Dan NomuraJorge Conde5 September 2023Dan Nomura is a distinguished professor at UC Berkeley and an Investigator at the Innovative Genomics Institute, specializing in Chemical Biology and Molecular Therapeutics. He serves as the Director of the Novartis-Berkeley Translational Chemical Biology Institute and founded Frontier Medicines and Vicinitas Therapeutics. He’s also a16z Bio+Health’s newest advisory partner. In this episode, Dan joins general partner Jorge Conde and investment partner Becky Pferdehirt to discuss how he got started working in chemical biology and chemoproteomics and his experience founding companies, along with leading lab and pharma collaborations. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
From Faculty to Founder: Building Startups from AcademiaVineeta Agarwala20 June 2023In this episode, taken from a live a16z event, Bio + Health general partner Vineeta Agarwala moderates a panel of UCSF faculty founders, including Michelle Arkin, Jimmie Ye, and Natalia Jura (full bios below). Together, they discuss fundraising, the decision to stay in or leave academia after founding a company, and their tips for managing the IP process. Michelle Arkin is a professor of pharmaceutical chemistry at UCSF, chair of the Department of Pharmaceutical Chemistry, and a co-director of the Small Molecule Discovery Center at UCSF. Professor Arkin is also a cofounder of both Elgin Therapeutics and Ambagon Therapeutics. Jimmie Ye is an associate professor of medicine at the Institute for Human Genetics at UCSF and an affiliate investigator at Gladstone Institutes. He is also the cofounder of Dropprint Genomics and Survey Genomics. Natalia Jura is a professor in the Department of Cell and Molecular Pharmacology and an investigator at the Cardiovascular Research Institute at UCSF. Professor Jura is also an associate director of the Quantitative Biosciences Institute. She is a cofounder of Rezo Therapeutics. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Adapting Biopharma to AI with Greg MeyersJorge Conde1 June 2023Today’s episode is with Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS). He is joined by a16z Bio + Health general partner Jorge Conde. Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Healthcare x Fintech with Julie Yoo and David HaberDavid Haber25 May 2023Healthcare payments are difficult, confusing, and opaque. But Julie and David discuss the ways that technology could change that for the better, and where they see the greatest opportunity for founders to solve big challenges. Additional reading: https://a16z.com/healthcare-meets-fintech/ https://a16z.com/2023/02/07/healthtech-x-fintechs-biggest-prize/ https://a16z.com/2022/06/01/payvidors-unbundled-opportunities-in-healthcare-fintech/
Reengineering Healthcare and Medicine with Technology with Vineeta AgarwalaVineeta Agarwala4 May 2023This is a crossover episode with The Bioverge Podcast, hosted by Neil Littman. Neil is joined by Vineeta Agarwala, general partner at a16z Bio + Health. Together, they chat about Vineeta's dual role as a clinician and investor, the adoption curve of digital therapeutics, how Vineeta thinks about platforms and a modular, engineering-driven approach to biotech, and much more.
Bio x American Dynamism with Katherine Boyle and David UlevitchDavid Ulevitch, Katherine Boyle27 April 2023Today’s episode is with a16z’s American Dynamism team: Katherine Boyle and David Ulevitch. Katherine is a general partner focused on national security, aerospace and defense, public safety, housing, education, and industrials. David is a general partner focused on companies promoting American dynamism, as well as enterprise and SaaS companies. They are joined by a16z Bio + Health general partner Vijay Pande, and editorial lead Olivia Webb. Together, we talk about the idea behind American Dynamism, how the American Dynamism team thinks about building within highly regulated industries, how trust is key to the procurement process, and how the team thinks about the regulation of AI.
Shaping Channel Partnerships with Sean DuffyJay Rughani20 April 2023Today’s episode is with Sean Duffy, cofounder and CEO of Omada Health. He is joined by a16z Bio + Health general partner Julie Yoo and investment partner Jay Rughani. Together, they talk about Sean’s three rules of partnerships, how Omada plans for large-scale implementation, and how Sean thinks about structuring the economic model of the partnership. This episode was recorded as part of our research into our forthcoming Go to Market Playbook, focused on channel partnerships. Stay tuned for that, which we’ll be releasing in the coming days at a16z.com/digital-health-builders .
Journal Club: Remodeling Oncogenic Transcriptomes with Ben Cravatt and Gene YeoVineeta Agarwala6 April 2023Today marks the reboot of our journal club series, so you can look forward to seeing these episodes as part of our regular feed. This episode is a scientific deep dive on recent research published by Ben Cravatt, Professor in the Department of Chemistry at the Scripps Research Institute and co-founder of a diverse suite of chemoproteomic companies such as Vividion and Belharra Therapeutics, and Gene Yeo, Professor of Cellular and Molecular Medicine at the University of California, San Diego and co-founder of Locana Bio, Eclipse Bio, and Trotana Therapeutics. Ben and Gene are joined by Vineeta Agarwala, general partner at a16z Bio + Health, and bio deal team member Bryan Faust. Together, they’ll discuss some unexpected mechanistic results of finding covalent binders to a class of proteins that we are just starting to understand — RNA binding proteins — and the subsequent translational implications that they described in a recent paper published by the Cravatt and Yeo labs in Nature Chemical Biology. The paper outlines a potentially new therapeutic approach that uses small molecules to fundamentally rewire transcriptional networks in cancer cells. Additional reading: Remodeling oncogenic transcriptomes by small molecules targeting NONO
Payments & Payors: Fintech's Role with Kurt AdamsDaisy Wolf2 March 2023In this episode, Kurt Adams, CEO of Optum Financial, chats with Daisy Wolf, investment partner for a16z Bio + Health, and Marc Andrusko, investment partner for a16z focused on fintech, about Optum Financial, how consumers might interact with fintech while seeking care or participating in healthy behaviors, and what a fintech-integrated version of the healthcare experience could look like. Additional reading from us: Payvidors, Unbundled: Opportunities in Healthcare Fintech Healthtech x Fintech’s Biggest Prize: The Financial Operating System for Healthcare
Going to Market in Healthcare: B2C2BJay Rughani16 February 2023In this episode, Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, talk to Kate Ryder, founder and CEO of Maven; Amanda Rees, cofounder and CEO of Bold Health; and Bill Porter, VP and GM, International, of Butterfly Network, about their B2C2B go-to-market motion. This episode was originally recorded in late 2021, but it's still really relevant to builders, especially those exploring the B2C2B go-to-market motion. We talked about B2C2B in-depth in the second chapter of our Digital Health Builders Founder's Playbooks, also available at: https://a16z.com/digital-health-builders/ And finally, our last chapter of the Founder's Playbooks is coming soon, so hit subscribe and stay tuned!
AI is Here. Now What?Vineeta Agarwala1 December 2022AI is here...so why isn't it in every clinic? Eric Topol talks with a16z Bio + Health general partners Vijay Pande and Vineeta Agarwala and editorial lead Olivia Webb about what's taking so long, where AI can help patients and providers the most, what needs to happen to speed up adoption, and whether data or policy is more likely to be an obstacle. Eric has written extensively about AI in healthcare, including in his most recent book Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again . He also writes a Substack focused on Covid research, called Ground Truths, linked below. Finally, as a marker of how AI and AI adoption has (and hasn't) changed over the last few years, check out Eric's 2019 interview with Vijay on the a16z Podcast, also linked below. Ground Truths - https://erictopol.substack.com/ a16z Podcast: AI and Your Doctor, Today and Tomorrow - https://a16z.com/2019/06/13/ai-doctor-deep-medicine-topol/
Regulatory Trends in TelehealthDaisy Wolf17 November 2022Perhaps no area of healthcare has undergone such a rapid shift as telehealth during the Covid pandemic. But as the world emerges from the public health emergency, it's an open question what will happen with the regulatory aspects of telehealth. Daisy Wolf, deal partner at a16z Bio + Health, talked to Sarah Thomas, general counsel at Sameday Health, about asynchronous telehealth, working with regulators, how counsel thinks about inducements, and more.
The Power of Patient-Centric HealthcareJay Rughani27 April 2021Today we are re-running an episode exploring a question that seems super straightforward, but that on closer examination reveals incredible complexity, and that is "how do we put the patient at the center of the healthcare system?” It almost seems counterintuitive, since aren’t patients always the center of healthcare? But healthcare is a strange industry, in that it is built with the fundamental goal of serving patients, but in many ways, the patient isn’t always the end customer of the system. In fact, the patient — and the patient’s voice — can often be lost or overlooked in the enormous, complex, convoluted business flows between a huge system of providers, in elaborate clinical work flows, in insurance coverage and reimbursements, and in high level policy debates. In this episode, a16z general partner Julie Yoo and deal team partner Jay Rughani talk with Freda Lewis Hall — a physician who was formerly Pfizer’s Chief Patient Officer and Chief Medical Officer; and who among many other roles was appointed by the Obama Administration to the Board of the Patient-Centered Outcomes Research Institute. They discuss what happens when you rethink the entire healthcare system from the patient’s point of view, from drug development to clinical trials to care delivery. What tools and new approaches can we use to truly put the patient at the center of the healthcare system? And how do we update our Flintstones healthcare system to match our Star Wars medicines?
We, the PatientsJay Rughani9 November 2020Healthcare is perhaps unique in that the entire system exists entirely to serve the patient... and yet, in many ways, that same patient is not the customer. In fact, the patient—and the patient's voice—can often be lost or overlooked in the enormous, complex, convoluted business flows, between a huge system of providers, in elaborate clinical work flows, in insurance coverage and reimbursements, or in high level policy debates. In this episode, a16z General Partner Julie Yoo and a16z partner Jay Rughani talk with Freda Lewis Hall—a physician; formerly Pfizer’s Chief Patient Officer and Chief Medical Officer; Chief Medical Officer at Vertex; and who among many other roles was appointed by the Obama Administration to the Board of the Patient-Centered Outcomes Research Institute (PCORI)—all about what happens when you rethink the entire healthcare system from the patient's point of view. We tell patients what they need, instead of asking them what they need—let alone listen to the answer. From drug development to healthcare delivery to clinical trials, what changes in our system when we think about everything from the patient’s perspective? How do we better understand what patients need, and better serve them? What tools and new approaches can we use to truly put the patient at the center of the healthcare system? Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.